Skip to main content

Table 2 Patient exposure to nintedanib

From: Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

Dose (once-daily)

Patients (n)

Dose (twice-daily)

Patients (n)

50 mg

1

150 mg × 2

4

100 mg

1

150 mg + 200 mg

4

200 mg

4

200 mg × 2

1

250 mg

4

250 mg × 2

7

300 mg

2

–

–

450 mg

2

–

–

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us